Matthew Miksic: Sure. Just a follow-up on Persona iQ. I think the number, I think maybe that was mentioned earlier was something like 1,000 implants. I mean that’s a pretty — it’s a pretty small percentage of total maybe 1%, less than 1% of your total implants a year. And I just want to get a sense of at what level do some of the data start coming through? Is it a couple of thousand implants? Is it 300 to 500 implants? When do you expect seeing some of the results you mentioned earlier in the call?
Ivan Tornos: Yes. Thank you, Matt. First and foremost, we don’t disclose the number of patients, but I’ll tell you, it’s far greater than 1,000 patients. When are we done with the limited market release? I think we’re about to complete that? The size matters more for certain claims than others, but I will tell you, we’ve got enough of a sample size to be able to engage in a full market release by 2024. What’s the expectation going forward, this is going to be a flagship product for Zimmer Biomet. We plan to see meaningful penetration of this technology. First in Knees, then in Hips and then at some point in Shoulders as well. What’s the right penetration? Again, we won’t disclose that. But given the unique technology, we will leverage this to the fullest.
Keri Mattox: Thanks, Ivan, and Matt thanks for your question. I think we’re almost at the bottom of the hour. I’ll actually turn it over to Bryan just for some closing remarks.
Bryan Hanson: Just maybe a quick summary to on what — but you were just talking about Suky, when we think about a normalized market. And we’re saying 2024 in our view, is not going to be normalized for 2 factors. You’re still going to have backlog that we’re going to have to pay attention to. We would deem backlog is a neutral to potentially negative depending on whether it stays the same or decreases. We don’t think there’s going to be an increase in it. And the second one is supply. That is going to be neutral to positive because as we continue to see supply benefits that will create a tailwind for next year. So those are pretty big variables that would tell us that we don’t have a normal year in 2024, but they’re offsetting.
So that’s the reason why we think 2024, even though “not normal” could look a lot like a normal year from a growth perspective. I just want to make sure that, that’s clear. And then just going to sum it up, first of all, thanks again for joining us this morning. And I think it’s pretty clear in the way that we talk about the business right now that we’re not just excited about where we are as a company, but the future of this company. And I think that’s really important. We’ve already made disciplined portfolio decisions that have increased the weighted average market growth of this business that’s already happened, and that gives us confidence in the growth of the organization, not just today but in the future. And the balance sheet says that we’re going to continue to be able to strengthen our position in those fast-growth markets and we will absolutely do that.
That is Phase 3 of the transformation. And the innovation pipeline as Ivan continues to talk about is as strong as it’s ever been, and that gives us the ability to drive mix benefit, pricing stability and competitive conversions. And when supply gets out of the way, that will even happen more. So we’re very excited about it. And I’ve been doing this long enough to know when the team has got that skip in their step. And they’ve got the ammunition to be able to drive the performance of the business sustainably. And we are in that place. Okay. With that, I’ll go ahead and close it out, and thanks for joining us.
Keri Mattox: Thanks, everyone. We’ll talk to you soon. And obviously, if you have any further questions, please don’t hesitate to reach out to the IR team.
Operator: Thank you for participating in today’s conference call. You may now disconnect.
